{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:51:07Z","timestamp":1794102667911,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01158-3","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:13:19Z","timestamp":1763730799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study"],"prefix":"10.1038","volume":"9","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1158_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain, P. & Wang, M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am. J. Hematol. 94, 710\u2013725 (2019).","journal-title":"Am. J. Hematol."},{"key":"1158_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","volume":"23","author":"ML Wang","year":"2022","unstructured":"Wang, M. L. et al. Ibrutinib\u2013rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 23, 406\u2013415 (2022).","journal-title":"Lancet Oncol."},{"key":"1158_CR3","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling, M. et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 403, 2293\u20132306 (2024).","journal-title":"Lancet"},{"key":"1158_CR4","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song, Y. et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 139, 3148\u20133158 (2022).","journal-title":"Blood"},{"key":"1158_CR5","doi-asserted-by":"crossref","unstructured":"Cheah, C. et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma: Updated results, subgroup analysis from bruin with >3 years follow-up from start of enrollment. Hematol. Oncol. 41, 153\u2013154 (2023).","DOI":"10.1002\/hon.3163_102"},{"key":"1158_CR6","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2019","unstructured":"Rule, S. et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 104, e211\u2013e214 (2019).","journal-title":"Haematologica"},{"key":"1158_CR7","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill, H. A. et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 4, 2927\u20132938 (2020).","journal-title":"Blood Adv."},{"key":"1158_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70310-9","volume":"10","author":"S Jeong","year":"2020","unstructured":"Jeong, S. et al. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: A multi-centre cohort study. Sci. Rep. 10, 13359 (2020).","journal-title":"Sci. Rep."},{"key":"1158_CR9","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares, P., Colomer, D. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. J. Clin. Invest 122, 3416\u20133423 (2012).","journal-title":"J. Clin. Invest"},{"key":"1158_CR10","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund, C. W. et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130, 1903\u20131910 (2017).","journal-title":"Blood"},{"key":"1158_CR11","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1182\/blood-2022-168002","volume":"140","author":"JL Koff","year":"2022","unstructured":"Koff, J. L. et al. Mutations of ATM confer a risk of inferior survival in patients with TP53-wild type Mantle cell lymphoma. Blood 140, 3500\u20133503 (2022).","journal-title":"Blood"},{"key":"1158_CR12","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.3324\/haematol.2018.212811","volume":"104","author":"T D\u2019Agaro","year":"2019","unstructured":"D\u2019Agaro, T. et al. A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. Haematologica 104, e410\u2013e414 (2019).","journal-title":"Haematologica"},{"key":"1158_CR13","unstructured":"Yi, S. et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J. Clin. Investig. 132, 1\u20138 (2022)."},{"key":"1158_CR14","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","volume":"23","author":"V Fern\u00e0ndez","year":"2005","unstructured":"Fern\u00e0ndez, V., Hartmann, E., Ott, G., Campo, E. & Rosenwald, A. Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J. Clin. Oncol. 23, 6364\u20136369 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1158_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","volume":"129","author":"K Krysiak","year":"2017","unstructured":"Krysiak, K. et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood 129, 473\u2013483 (2017).","journal-title":"Blood"},{"key":"1158_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1078-0432.CCR-20-2403","volume":"27","author":"JS Morris","year":"2021","unstructured":"Morris, J. S. et al. Development and validation of a gene signature classifier for consensus molecular subtyping of colorectal carcinoma in a CLIA-certified setting. Clin. Cancer Res. 27, 120\u2013130 (2021).","journal-title":"Clin. Cancer Res"},{"key":"1158_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"1158_CR18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"1158_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3324\/haematol.2019.224535","volume":"106","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser, F. et al. Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. Haematologica 106, 859\u2013862 (2021).","journal-title":"Haematologica"},{"key":"1158_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12185-020-02994-8","volume":"113","author":"J Cortes","year":"2021","unstructured":"Cortes, J. et al. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J. Hematol. 113, 92\u201399 (2021).","journal-title":"Int J. Hematol."},{"key":"1158_CR21","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/ijc.24748","volume":"125","author":"D Bai","year":"2009","unstructured":"Bai, D., Ueno, L. & Vogt, P. K. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int. J. Cancer 125, 2863\u20132870 (2009).","journal-title":"Int. J. Cancer"},{"key":"1158_CR22","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1158\/1535-7163.MCT-12-0920","volume":"12","author":"G Wang","year":"2013","unstructured":"Wang, G., et al. PI3K stimulates DNA synthesis and cell-cycle progression via its p55PIK regulatory subunit interaction with PCNA. Mol. Cancer Ther. 12, 2100\u20132109 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"1158_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/gcc.22123","volume":"53","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy, C. et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer 53, 106\u2013116 (2014).","journal-title":"Genes Chromosomes Cancer"},{"key":"1158_CR24","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","volume":"38","author":"M Khouja","year":"2024","unstructured":"Khouja, M. et al. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: Results from the EU-MCL network trials. Leukemia 38, 2675\u20132684 (2024).","journal-title":"Leukemia"},{"key":"1158_CR25","doi-asserted-by":"crossref","unstructured":"Hill, H. A. et al. Integrative prognostic machine-learning models in Mantle cell lymphoma. Cancer Res. Commun. 3, 1435\u20131446 (2023).","DOI":"10.1158\/2767-9764.CRC-23-0083"},{"key":"1158_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40164-021-00215-4","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma. Exp. Hematol. Oncol. 10, 20 (2021).","journal-title":"Exp. Hematol. Oncol."},{"key":"1158_CR27","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/blood-2019-130512","volume":"134","author":"K Nomie","year":"2019","unstructured":"Nomie, K. et al. Tumor microenvironment molecular signatures that define therapeutic resistance in Mantle cell lymphoma. Blood 134, 2762\u20132762 (2019).","journal-title":"Blood"},{"key":"1158_CR28","doi-asserted-by":"publisher","first-page":"8055","DOI":"10.1200\/JCO.2020.38.15_suppl.8055","volume":"38","author":"K Nomie","year":"2020","unstructured":"Nomie, K. et al. Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance. J. Clin. Oncol. 38, 8055\u20138055 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1158_CR29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.21037\/atm-22-5815","volume":"10","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Identification of immune-related genes and development of a prognostic model in mantle cell lymphoma. Ann. Transl. Med. 10, 1323 (2022).","journal-title":"Ann. Transl. Med."},{"key":"1158_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00927-2","volume":"13","author":"P Jain","year":"2023","unstructured":"Jain, P. et al. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 13, 156 (2023).","journal-title":"Blood Cancer J."},{"key":"1158_CR31","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","volume":"22","author":"CU Niemann","year":"2016","unstructured":"Niemann, C. U. et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib-findings from an investigator-initiated phase II study. Clin. Cancer Res 22, 1572\u20131582 (2016).","journal-title":"Clin. Cancer Res"},{"key":"1158_CR32","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu, Y. T. & Sun, Z. J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11, 5365\u20135386 (2021).","journal-title":"Theranostics"},{"key":"1158_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1158_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52814-w","volume":"14","author":"T Abd El-Hafeez","year":"2024","unstructured":"Abd El-Hafeez, T., Shams, M. Y., Elshaier, Y. A. M. M., Farghaly, H. M. & Hassanien, A. E. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs. Sci. Rep. 14, 2428 (2024).","journal-title":"Sci. Rep."},{"key":"1158_CR35","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1158_CR36","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature09534","volume":"467","author":"GR Abecasis","year":"2010","unstructured":"Abecasis, G. R. et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061\u20131073 (2010).","journal-title":"Nature"},{"key":"1158_CR37","unstructured":"Chen, S. et al. A genome-wide mutational constraint map quantified from variation in 76,156 human genomes. bioRxiv 2022: 2022.2003.2020.485034."},{"key":"1158_CR38","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLOS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLOS Comput. Biol."},{"key":"1158_CR39","doi-asserted-by":"crossref","unstructured":"Benjamini Y., Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annals Stat. 29, 1165\u20131188 (2001).","DOI":"10.1214\/aos\/1013699998"},{"key":"1158_CR40","first-page":"10","volume":"1","author":"K Blighe","year":"2019","unstructured":"Blighe, K., Rana, S. & Lewis, M. EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling. R. Package version 1, 10\u201318129 (2019).","journal-title":"R. Package version"},{"key":"1158_CR41","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"1158_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1158_CR43","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2015","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457\u2013D462 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1158_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR45","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41419-023-06233-w","volume":"14","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death Dis. 14, 714 (2023).","journal-title":"Cell Death Dis."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01158-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01158-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01158-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:13:21Z","timestamp":1763730801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01158-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01158-3","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W. is consultant to AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Deciphera, InnoCare, Janssen, Kite Pharma, Leukemia & Lymphoma Society, Lilly, Merck, Milken Institute, Oncternal, Parexel, Pepromene Bio, Pharmacyclics, and VelosBio, and he has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, Vincerx. M.W. also received a speaker honorarium from AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Dava Oncology, Eastern Virginia Medical School, IDEOlogy Health, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Meeting Minds Experts, MJH Life Sciences, Merck, Moffit Cancer Center, Oncology Specialty Group, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), and Studio ER Congressi. The remaining authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}